Abstract

The underuse of BRCA testing in patients diagnosed with breast and ovarian cancer remains a critical issue in modern oncology. Inherited mutations in the BRCA1 and BRCA2 genes significantly elevate the risk of developing these cancers, warranting early identification and appropriate management. This study aims to assess the current extent of BRCA testing underutilization, its underlying causes, and potential implications for patient outcomes. By analyzing a diverse range of clinical and socio-economic factors contributing to this underuse, we seek to propose strategies for improving testing rates and promoting personalized cancer care. Addressing the underuse of BRCA testing has the potential to enhance early detection, risk assessment, and tailored treatment, ultimately leading to improved survival rates and better quality of life for individuals at risk.